ACST (Acasti Pharma Inc.) רווח למניה בארבעת הרבעונים האחרונים

Acasti Pharma (ACST) is developing the innovative GTX-104 gel for local therapy, integrating advanced drug delivery methods into the treatment of rare pathologies. Annual EPS (TTM) growth statistics demonstrate profit dynamics, where the value -119.00 represents the current figure. Currently, Acasti Pharma is independently advancing its cardiology pipeline, limiting external interaction solely to the licensing of drug distribution rights.
Acasti Pharma Inc. - פילוחים אנליטיים ומדדי מפתח (ACST)

A fundamental stress test of assets requires an analysis of earnings sustainability over the long term. Acasti Pharma (ACST) currently has no commercial sales, focusing instead on the development of drugs for neuropathies. The trailing twelve-month (TTM) earnings per share dynamics measure the rate of change in net income relative to the previous year. By analyzing the annual EPS TTM growth rate, an investor can determine the capital burn rate. The future capitalization of Acasti Pharma (ACST) depends exclusively on clinical success.